Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kertscher HP and Ostermann G | [Synthesis and thrombocyte aggregating action of stereoisomers of PAF-acether]. | 1986 | Pharmazie | pmid:3786385 |
Kertscher HP and Ostermann G | [PAF-antagonists with phospholipid structure. 2. Phospholipids with heteroarene head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationships]. | 1991 | Pharmazie | pmid:1803385 |
Kertscher HP and Ostermann G | [PAF-antagonists with phospholipid structure. 3. Phospholipids with heterocyclane head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationship]. | 1991 | Pharmazie | pmid:1811226 |
Kertscher HP and Ostermann G | [Synthesis and biological activity of isomeric structural analogs of platelet activating factor]. | 1985 | Pharmazie | pmid:3991788 |
Kertscher HP | [PAF-antagonists with lipid structure. 6. Alkylpropandiol lipids with acyl- and ether- structures at the C-3 position and heterocyclic head groups; synthesis, characterization and structure-activity relationship]. | 1997 | Pharmazie | pmid:9411454 |
Kertscher HP et al. | [Synthesis and thrombocyte-aggregating action of a structural analog of platelet activating factor with a modified head group]. | 1988 | Pharmazie | pmid:3380866 |
Kertscher HP et al. | [PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship]. | 1992 | Pharmazie | pmid:1615020 |
Asai Y | Formation of spherical micelles composed of the novel platelet activating factor receptor antagonist, E5880. | 2005 | Pharmazie | pmid:15801673 |
Kertscher HP and Ostermann G | [Synthesis and platelet aggregating activity of structural analogs of platelet-activating factor with a heterocyclic head group]. | 1987 | Pharmazie | pmid:3438334 |
Wagner G et al. | [Synthesis of N-(2-carboxy-thieno(2,3-b)pyridin-3-yl)-formamidines corresponding alkyl esters with antianaphylactic activity]. | 1993 | Pharmazie | pmid:8493283 |
Chatterjee SS et al. | Structure-activity studies with Ginkgo biloba extract constituents as receptor-gated chloride channel blockers and modulators. | 2003 | Pharmacopsychiatry | pmid:13130392 |
Ueno M et al. | Antiallergic action of betotastine besilate (TAU-284) in animal models: A comparison with ketotifen. | 1998 | Pharmacology | pmid:9730778 |
Shibamoto T et al. | PAF, rather than histamine, participates in mouse anaphylactic hypotension. | 2008 | Pharmacology | pmid:18583921 |
Kagoshima M et al. | Effects of Y-24180, a long-acting and potent antagonist to platelet-activating factor, on immediate asthmatic response in guinea pigs. | 1997 | Pharmacology | pmid:9065955 |
Singh N et al. | Possible mechanism of alprazolam-induced amnesia in mice. | 1998 | Pharmacology | pmid:9467187 |
Merlos M et al. | Comparative study of the effect of CV-6209, a specific PAF-antagonist, on rat paw edema caused by different phlogogen agents. | 1990 | Pharmacology | pmid:1697076 |
Kagoshima M et al. | Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action. | 1997 | Pharmacology | pmid:9380772 |
Achterrath-Tuckermann U et al. | Azelastine, a new antiallergic/antiasthmatic agent, inhibits PAF-acether-induced platelet aggregation, paw edema and bronchoconstriction. | 1988 | Pharmacology | pmid:3380879 |
Suzuki S et al. | Effect of a platelet-activating factor antagonist, WEB 2086, on inhibition of active oxygen generation in human polymorphonuclear leukocytes. | 1994 | Pharmacology | pmid:8134402 |
Capasso F et al. | Effect of senna is not mediated by platelet-activating factor. | 1993 | Pharmacology | pmid:8234442 |
Cheng HH et al. | Defect in regulation of Ca2+ movement in platelets from patients with systemic lupus erythematosus. | 2005 | Pharmacology | pmid:15591819 |
Pei HX et al. | Ginkgolide B Reduces the Degradation of Membrane Phospholipids to Prevent Ischemia/Reperfusion Myocardial Injury in Rats. | 2015 | Pharmacology | pmid:26382046 |
Bannenberg G et al. | Hydrogen peroxide-induced broncho- and vasoconstriction in the isolated perfused and ventilated guinea pig lung. | 1993 Apr-May | Pharmacol. Toxicol. | pmid:8372054 |
Cakici I et al. | Effects of platelet-activating factor antagonists WEB 2086 and BN 50730 on digoxin-induced arrhythmias. | 1995 | Pharmacol. Toxicol. | pmid:7479573 |
Chen SF and Ruan YJ | 1 alpha,25-Dihydroxyvitamin D3 decreases scalding- and platelet-activating factor-induced high vascular permeability and tissue oedema. | 1995 | Pharmacol. Toxicol. | pmid:7479576 |
Moilanen E and Kankaanranta H | Tolfenamic acid and leukotriene synthesis inhibition. | 1994 | Pharmacol. Toxicol. | pmid:7816785 |
Abu-Zidan FM et al. | BB-882 is a potent antagonist of the haemodynamic changes induced by platelet-activating factor in pigs. | 1996 | Pharmacol. Toxicol. | pmid:8685082 |
Monteiro HS et al. | Glomerular effects of cholera toxin in isolated perfused rat kidney: a potential role for platelet activating factor. | 1999 | Pharmacol. Toxicol. | pmid:10522748 |
Morley J et al. | Platelet activating factor and airway smooth muscle. | 1989 | Pharmacol. Ther. | pmid:2646651 |
Williams FM | Neutrophils and myocardial reperfusion injury. | 1996 | Pharmacol. Ther. | pmid:8981567 |
Braquet P et al. | Perspectives in platelet-activating factor research. | 1987 | Pharmacol. Rev. | pmid:3303066 |
Saeed SA et al. | Anti-thrombotic and anti-inflammatory activities of protopine. | 1997 | Pharmacol. Res. | pmid:9368908 |
Caruso A et al. | Protective effect of propionyl-L-carnitine against PAF-induced rat paw oedema. | 1995 | Pharmacol. Res. | pmid:7784308 |
SariahmetoÄŸlu M et al. | Effects of WEB 2086 on the protective role of preconditioning against arrhythmias in rats. | 1998 | Pharmacol. Res. | pmid:9782066 |
Qian C et al. | Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. | 2001 | Pharmacol. Res. | pmid:11529688 |
Mest HJ et al. | WEB 2086, a novel specific PAF antagonist, prevents PAF induced arrhythmogenicity. | 1990 Jul-Aug | Pharmacol. Res. | pmid:2402478 |
Lagente V et al. | Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats. | 1989 Sep-Oct | Pharmacol. Res. | pmid:2594614 |
Mest HJ et al. | Effect of BN 52256 and other mediator antagonists on ouabain-induced cardiac arrhythmia in a model of anaphylaxis in guinea-pigs. | 1992 Feb-Mar | Pharmacol. Res. | pmid:1635894 |
Lograno MD et al. | Effects of prostaglandins and PAF on the contractility of the bovine ciliary muscle. | 1992 Feb-Mar | Pharmacol. Res. | pmid:1635897 |
Montesi L et al. | Human platelet activation by PAF: receptor characterization. | 1989 Nov-Dec | Pharmacol. Res. | pmid:2561199 |
Berti F et al. | Cardiovascular and pulmonary activity of platelet-activating factor (PAF-acether) and its derivatives. | 1986 | Pharmacol Res Commun | pmid:3749244 |
Foegh ML et al. | The causal role of PAF and leukotrienes in acute cardiac allograft rejection in rats. | 1986 | Pharmacol Res Commun | pmid:3534895 |
Brambilla A et al. | WEB 2086. A potent PAF antagonist exerts protective effect toward PAF-induced gastric damage. | 1987 | Pharmacol Res Commun | pmid:3588650 |
Baranes J et al. | The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021. | 1986 | Pharmacol Res Commun | pmid:3763677 |
Danko G et al. | Effect of the PAF antagonists, CV-3988 and L-652,731 on the pulmonary and hematological responses to guinea pig anaphylaxis. | 1988 | Pharmacol Res Commun | pmid:3174804 |
Bussolino F et al. | Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells. | 1986 | Pharmacol Res Commun | pmid:3490673 |
Riedel A et al. | The effect of the specific PAF antagonist BN 52021 and the calcium blocker diltiazem on PAF induced arrhythmogenicity. | 1987 | Pharmacol Res Commun | pmid:3441484 |
Godfroid JJ et al. | Synthesis of ether phospholipids. | 1986 | Pharmacol Res Commun | pmid:3774838 |
PAF and leukotrienes '85. Proceedings of the meeting. Paris, September 27th 1985. | 1986 | Pharmacol Res Commun | pmid:3774839 | |
Vilain B et al. | Pharmacological control of the in vivo passive anaphylactic shock by the PAF-acether antagonist compound BN 52021. | 1986 | Pharmacol Res Commun | pmid:3774840 |
Bessin P | PAF-acether and leukotriene participation in acute circulatory shock. | 1986 | Pharmacol Res Commun | pmid:3774841 |
Goldstein RE et al. | Coronary and pulmonary vascular effects of leukotrienes and PAF-acether. | 1986 | Pharmacol Res Commun | pmid:3774842 |
Plante GE et al. | Hemodynamic effects of PAF-acether. | 1986 | Pharmacol Res Commun | pmid:3774843 |
Sanchez Crespo M et al. | Evidence of a role for PAF-acether in the pathophysiology of the shock state. | 1986 | Pharmacol Res Commun | pmid:3774844 |
Adnot S et al. | Interference of BN 52021, a PAF-acether antagonist, with endotoxin-induced hypotension in the guinea-pig. | 1986 | Pharmacol Res Commun | pmid:3774845 |
Rainsford KD | Relative roles of leukotrienes and platelet activating factor in experimentally-induced gastric ulceration. | 1986 | Pharmacol Res Commun | pmid:3774846 |
Page CP and Morley J | Evidence favouring PAF rather than leukotrienes in the pathogenesis of asthma. | 1986 | Pharmacol Res Commun | pmid:3774847 |
Haye-Legrand I et al. | Production of PAF-acether and leukotrienes by cultured mouse macrophages. | 1986 | Pharmacol Res Commun | pmid:3774848 |
Dupont L et al. | Crystal and molecular structure of BN 52021, a PAF-acether antagonist. Comparison with the conformation of Kadsurenone and related compounds. | 1986 | Pharmacol Res Commun | pmid:3774849 |
Bruynzeel PL et al. | Platelet-activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. | 1986 | Pharmacol Res Commun | pmid:3774850 |
Etienne A et al. | The relative role of PAF-acether and icosanoids in septic shock. | 1986 | Pharmacol Res Commun | pmid:3774851 |
Maes L et al. | Endogenic PAF-acether production by guinea pig endothelial cells in experimental arterial thrombosis. | 1986 | Pharmacol Res Commun | pmid:3774852 |
Uhlig S et al. | Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung. | 2005 | Pharmacol Rep | pmid:16415501 |
Stafforini DM | PAF acetylhydrolase gene polymorphisms and asthma severity. | 2001 | Pharmacogenomics | pmid:11535107 |
Semini G et al. | Impact of alkylphospholipids on the gene expression profile of HaCaT cells. | 2011 | Pharmacogenet. Genomics | pmid:21681147 |
Weber N | [A platelet-activating factor--a physiologically active ether lipid]. | 1986 | Pharm Unserer Zeit | pmid:3749211 |
Nordin N et al. | Platelet-activating factor (PAF) receptor binding activity of the roots of Enicosanthellum pulchrum. | 2012 | Pharm Biol | pmid:22103812 |
Alonso-Torre SR and Trautmann A | Rapid refilling of Ca2+ stores in macrophages stimulated by ATP involves the sequential activation of phospholipase D and protein kinase C. | 1995 | Pflugers Arch. | pmid:7675633 |
Randriamampita C et al. | Cyclic-GMP-dependent refilling of calcium stores in macrophages. | 1991 | Pflugers Arch. | pmid:1647519 |
Kester M et al. | The potentiation of arterial contraction with platelet activating factor. | 1984 | Pflugers Arch. | pmid:6718228 |
Hermoso M et al. | Platelet activating factor increases ciliary activity in the hamster oviduct through epithelial production of prostaglandin E2. | 2001 | Pflugers Arch. | pmid:11484763 |
Asimakopoulos G et al. | Inhibition of neutrophil L-selectin shedding: a potential anti-inflammatory effect of aprotinin. | 2000 | Perfusion | pmid:11131212 |
Quigley RL et al. | Cardiopulmonary bypass with adequate flow and perfusion pressures prevents endotoxaemia and pathologic cytokine production. | 1995 | Perfusion | pmid:7795310 |
Sung CP et al. | CGRP stimulates the adhesion of leukocytes to vascular endothelial cells. | 1992 May-Jun | Peptides | pmid:1326102 |
Cox CP et al. | VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). | 1984 Mar-Apr | Peptides | pmid:6206481 |
Sato A et al. | Angiotensin peptides attenuate platelet-activating factor-induced inflammatory activity in rats. | 2015 | Peptides | pmid:26348270 |
Pirotzky E et al. | [Renal diseases and platelet activating factor]. | 1989 | Pediatrie | pmid:2740184 |
Ozturk H et al. | PAF antagonist BN-52021 reduces intercellular adhesion molecule-1 expression and oxidative stress in rats with reperfusion damage due to unilateral testicular torsion. | 2006 | Pediatr. Surg. Int. | pmid:16369775 |
McFall TL et al. | Effect of group B streptococcal type-specific antigen on polymorphonuclear leukocyte function and polymorphonuclear leukocyte-endothelial cell interaction. | 1987 | Pediatr. Res. | pmid:3037472 |
Caplan MS et al. | Effect of polyunsaturated fatty acid (PUFA) supplementation on intestinal inflammation and necrotizing enterocolitis (NEC) in a neonatal rat model. | 2001 | Pediatr. Res. | pmid:11328947 |
Wang H et al. | Platelet-activating factor (PAF) up-regulates plasma and tissue PAF-acetylhydrolase activity in the rat: effect of cycloheximide. | 1997 | Pediatr. Res. | pmid:9357930 |
Liu XH et al. | Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. | 2001 | Pediatr. Res. | pmid:11385142 |
Claud EC et al. | Platelet-activating factor regulates chloride transport in colonic epithelial cell monolayers. | 2002 | Pediatr. Res. | pmid:12149490 |
Brus F et al. | Activation of circulating polymorphonuclear leukocytes in preterm infants with severe idiopathic respiratory distress syndrome. | 1996 | Pediatr. Res. | pmid:8929866 |
Liu XH et al. | The platelet-activating factor antagonist BN 52021 attenuates hypoxic-ischemic brain injury in the immature rat. | 1996 | Pediatr. Res. | pmid:8947953 |
Stambouly JJ et al. | Sustained effects of platelet-activating factor infusion in piglets. | 1991 | Pediatr. Res. | pmid:1945566 |
Kikawa Y et al. | Leukotriene B4 biosynthesis in polymorphonuclear leukocytes from blood of umbilical cord, infants, children, and adults. | 1986 | Pediatr. Res. | pmid:3012451 |
Harris MC et al. | Diminished actin polymerization by neutrophils from newborn infants. | 1993 | Pediatr. Res. | pmid:8433856 |
Tan ND and Davidson D | Comparative differences and combined effects of interleukin-8, leukotriene B4, and platelet-activating factor on neutrophil chemotaxis of the newborn. | 1995 | Pediatr. Res. | pmid:7478787 |
MacKendrick W et al. | Endogenous nitric oxide protects against platelet-activating factor-induced bowel injury in the rat. | 1993 | Pediatr. Res. | pmid:8233729 |
Furukawa M et al. | Platelet-activating factor-induced ischemic bowel necrosis: the effect of platelet-activating factor acetylhydrolase. | 1993 | Pediatr. Res. | pmid:8233731 |
Bradley LM et al. | Influence of thromboxane A2 receptor antagonism on pulmonary vasoconstrictor responses. | 1989 | Pediatr. Res. | pmid:2587116 |
Lu J et al. | Dual roles of endogenous platelet-activating factor acetylhydrolase in a murine model of necrotizing enterocolitis. | 2010 | Pediatr. Res. | pmid:20531249 |
Viswanath M et al. | Reduction of hypoxic-ischemic brain swelling in the neonatal rat with PAF antagonist WEB 2170: lack of long-term protection. | 2000 | Pediatr. Res. | pmid:10879808 |
Caplan MS et al. | Endotoxin and hypoxia-induced intestinal necrosis in rats: the role of platelet activating factor. | 1992 | Pediatr. Res. | pmid:1603619 |
Abraham WM and Wanner A | Inflammatory mediators of asthma. | 1988 | Pediatr. Pulmonol. | pmid:2455882 |
Smith JM et al. | Platelet-activating factor and Escherichia coliO157:H7 infections. | 2002 | Pediatr. Nephrol. | pmid:12478356 |
Svetlov SI et al. | Decreased intraplatelet Ca2+ release and ATP secretion in pediatric nephrotic syndrome. | 1999 | Pediatr. Nephrol. | pmid:10353406 |
Hsueh W et al. | Neonatal necrotizing enterocolitis: clinical considerations and pathogenetic concepts. | 2003 Jan-Feb | Pediatr. Dev. Pathol. | pmid:12424605 |
Hsueh W et al. | Necrotizing enterocolitis of the newborn: pathogenetic concepts in perspective. | 1998 Jan-Feb | Pediatr. Dev. Pathol. | pmid:10463267 |